ILMN News & Events

Illumina and the Center for Data-Driven Discovery in Biomedicine, or D3b, announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care. Through this initiative, D3b is analyzing 100,000 whole genomes from pediatric patients using Illumina software solutions. This is one of the largest unified genomic datasets ever assembled. D3b and Illumina are enabling discovery at a scale not previously possible, making the resulting insights available through the Gabriella Miller Kids First Data Resource Center. This data empowers researchers and clinicians to uncover the biological origins of rare disease and cancer and translate findings for pediatric precision medicine. The dataset will include whole genomes from patients with rare congenital conditions and cancers, collected through federally-funded programs, including the Kids First DRC and the Children's Brain Tumor Network. The samples are being analyzed with DRAGEN v4.4 and Illumina Connected Analytics to create a comprehensive dataset with the accuracy, speed, and scale necessary for meaningful, cross-sample insights.

Illumina announced changes to its Board of Directors. Frances Arnold, PhD, Robert Epstein, MD, and Gary Guthart, PhD, will retire from the Board in connection with the company's upcoming annual meeting of shareholders, and the Board has nominated David King to be elected as a member of the Board. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings, and currently serves as a director and chair of both Privia Health and AmSurg Corporation, and as a director of Smith & Nephew.

Illumina (ILMN) and Labcorp (LH) announced an expanded collaboration to advance precision oncology through applications of next-generation sequencing solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Illumina announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization. "The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer's environment and enable members to benefit from preventive genomics at a personalized level," said Javier de Echevarria, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.